Pemafibrate for prevention of atherosclerotic diseases in patients with ischemic stroke or transient ischemic attack

Pemafibrate for prevention of atherosclerotic diseases in patients with stroke or transient ischemic attack - Pemafibrate for prevention of atherosclerotic diseases in stroke patients (PPAR-Stroke)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040619

Enrollment

200

Registered

2020-06-01

Start date

2019-09-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke, transient ischemic attack

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with ischemic stroke or transient ischemic attack who started to receive pemafibrate for atherogenic dyslipidemia. Statin therapy is prioritized if the patient has hyper LDL cholesterolemia.

Exclusion criteria

Exclusion criteria: 1. Contraindications for pemafibrate (e.g., allergy to the drug, severe kidney dysfunction, pregnancy etc.) 2. Patients who have a history of or plan to undergo carotid endarterectomy/carotid stenting 3. Patients who had received pemafibrate before index event

Design outcomes

Primary

Measure	Time frame
Carotid intima media thickness	—

Secondary

Measure	Time frame
1. Major cardiovascular events (nonfatal stroke, nonfatal coronary artery disease, nonfatal peripheral artery disease, and vascular death) and all cause death 2. Lipid and glucose metabolites and inflammatory markers in blood samples 3. Brain magnetic resonance imaging and angiography findings 4. New onset of dementia 5. New onset of atrial fibrillation	—

Countries

Japan

Contacts

Public ContactTakao Hoshino

Tokyo Women's Medical University Department of Neurology

hoshino.takao@twmu.ac.jp0333538111

Outcome results